RxDoctor Payments Data

Adam Jangula

Psychiatry · Minot, NDNPI 1124467741

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 22 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) at 25.1% of the total.

$390in general payments, 2019–2025

Across 22 payments — averaging $17.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$98
  • Lundbeck LLC$84
  • Neurocrine Biosciences, Inc.$47
  • Alkermes, Inc.$44
  • Takeda Pharmaceuticals U.S.A., Inc.$34
  • Avanir Pharmaceuticals, Inc.$18
  • plus $64 from 4 others

What the payments were for

  • Food & beverage$390100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$390 in reported general payments places this provider in the 70th percentile of 63 psychiatry providers in North Dakota.

See all psychiatry providers in North Dakota

Medicare billing

Part B allowed, 2024
$15,799
Medicare patients
36
Services billed
171

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate50$170,868
Abilify MaintenaAripiprazole29$76,369
LybalviOlanzapine/Samidorphan Malate22$32,867
VraylarCariprazine Hcl18$27,039
TrintellixVortioxetine Hydrobromide14$6,736
Olanzapine83$4,932
Paliperidone ErPaliperidone30$4,274
Aripiprazole35$2,678
Clozapine36$2,451
Vilazodone Hcl24$2,371
Oxcarbazepine34$2,099
Divalproex Sodium ErDivalproex Sodium39$1,906
Ziprasidone Hcl22$1,409
Quetiapine Fumarate102$1,186
Haloperidol Decanoate26$950

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$17$170,86850 claims
Alkermes, Inc.Lybalvi$44$32,86722 claims
AbbVieVraylar$16$27,03918 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$34$6,73614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 63 psychiatry providers in North Dakota.

Other psychiatry in Minot

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →